Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2020

01-04-2020 | Lymphoma | Images

Synchronous T-Non Hodgkins Lymphoma and Multiple Myeloma: A Rare Association

Authors: Abhimanyu Sharma, Namrata Kaul, Neha Singh, Anurag Mehta, Gurudutt Gupta

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Login to get access

Excerpt

69 years old female presented with pallor and generalized lymphadenopathy for 1 month. Hemogram showed Hb: 7.9 g/dl, TLC: 13,200/cumm and Platelet count: 50,000/cumm; DLC: N66 L19, M6, Atypical Plasmacytoid Cells 09. Peripheral smear shows rouleaux formation. Serum LDH, uric acid and creatinine were mildly elevated (297 U/L, 8.3 mg/dl and 1.2 mg/dl respectively) and serum calcium was reduced (3.55 mg/dl). PET-Scan showed metabolically active supra/infra diaphragmatic lymphadenopathy with extranodal and splenic involvement and diffusely increased tracer uptake in bone marrow along with mild bilateral pleural effusion. In view of generalized lymphadenopathy, a provisional diagnosis of Non Hodgkins Lymphoma was considered, and further work-up was advised for confirmation. Cervical lymph node biopsy showed effacement of nodal architecture with large-sized neoplastic lymphoid cells in a background of histiocytes, lymphocytes and plasma cells. On immunohistochemistry, these atypical lymphoid cells were positive for CD3, CD4, CD5, CD30 and TIA-1 and negative for ALK, EMA, CD8, PD-1, CD20, CD10 and EBER-ISH with proliferative index of around 70% (Fig. 1). A diagnosis of ALK-Negative Anaplastic Large Cell Lymphoma was made. Bone marrow evaluation as part of staging work-up revealed 50% atypical plasmacytoid cells with round, central to eccentric nucleus, deeply blue cytoplasm and inconspicuous nucleoli. Hypercellular bone marrow biopsy showed interstitial as well as diffuse infiltration with plasmacytoid cells including atypical and immature forms along with two to three nodular intertrabecular lymphoid aggregates. On IHC, the plasma cells were strongly and diffusely positive for CD138 with clonal restriction for lambda light chain (Fig. 2). The lymphoid aggregates were positive for both CD3 and CD20 suggestive of their reactive nature. In view of negative expression of CD 20 and CD30 in the atypical plasmacytoid cells, the possibility of other differentials such as lymphoplasmacytic lymphoma and small cell variant of anaplastic large cell lymphoma were virtually ruled out. Serum protein electrophoresis showed M band in gamma and beta-2 region. Hence, a final diagnosis of synchronous ALK-Negative ALCL with Plasma cell Myeloma was made. The patient died due to tumor lysis syndrome within next few days.
Literature
1.
go back to reference Mahindra AK, Sohani Toomey AR, Michaelson CE et al (2011) B cell lymphoma in association with multiple myeloma: analysis of the biologic relationship. Blood 118(21):1590CrossRef Mahindra AK, Sohani Toomey AR, Michaelson CE et al (2011) B cell lymphoma in association with multiple myeloma: analysis of the biologic relationship. Blood 118(21):1590CrossRef
2.
go back to reference Wilkinson JA, Fiala MA, Vij R et al (2015) Synchronous and metachronous second malignancies in multiple myeloma (MM). J Clin Oncol 33(15_suppl):e19535–e19535CrossRef Wilkinson JA, Fiala MA, Vij R et al (2015) Synchronous and metachronous second malignancies in multiple myeloma (MM). J Clin Oncol 33(15_suppl):e19535–e19535CrossRef
3.
go back to reference Miyatake J, Inoue H, Serizawa K et al (2018) Synchronous occurrence of mycosis fungoides, diffuse large b cell lymphoma and acute myeloid leukemia. Intern Med 57(10):1445–1453CrossRef Miyatake J, Inoue H, Serizawa K et al (2018) Synchronous occurrence of mycosis fungoides, diffuse large b cell lymphoma and acute myeloid leukemia. Intern Med 57(10):1445–1453CrossRef
4.
go back to reference Hwang JE, Cho SH, Kim OK et al (2008) Newly developed multiple myeloma in a patient with primary T-cell lymphoma of bone. J Korean Med Sci 23(3):544–547CrossRef Hwang JE, Cho SH, Kim OK et al (2008) Newly developed multiple myeloma in a patient with primary T-cell lymphoma of bone. J Korean Med Sci 23(3):544–547CrossRef
5.
go back to reference Bryant E, Ronan SG, Iossifides IA (1982) Plasma cell myeloma in a patient with a cutaneous T-cell lymphoma. Cancer 50:2122–2125CrossRef Bryant E, Ronan SG, Iossifides IA (1982) Plasma cell myeloma in a patient with a cutaneous T-cell lymphoma. Cancer 50:2122–2125CrossRef
6.
go back to reference Wickenhauser C, Borchmann P, Diehl V, Scharffetter-Kochanek K (1999) Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphoma. Leuk Lymphoma 35:201–206CrossRef Wickenhauser C, Borchmann P, Diehl V, Scharffetter-Kochanek K (1999) Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphoma. Leuk Lymphoma 35:201–206CrossRef
7.
go back to reference Qian YW, Siegel D, Bhattacharyya P (2006) Pathologic diagnosis: CD30-positive cutaneous large cell lymphoproliferative disorder. Arch Pathol Lab Med 130:e43 Qian YW, Siegel D, Bhattacharyya P (2006) Pathologic diagnosis: CD30-positive cutaneous large cell lymphoproliferative disorder. Arch Pathol Lab Med 130:e43
Metadata
Title
Synchronous T-Non Hodgkins Lymphoma and Multiple Myeloma: A Rare Association
Authors
Abhimanyu Sharma
Namrata Kaul
Neha Singh
Anurag Mehta
Gurudutt Gupta
Publication date
01-04-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01160-3

Other articles of this Issue 2/2020

Indian Journal of Hematology and Blood Transfusion 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine